TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

This study looks at outcomes for patients with ruptured liver cancer (hepatocellular carcinoma that has burst and caused bleeding) who are treated with a combination of tumor-directed embolization (TACE), a targeted drug (lenvatinib), and an immunotherapy drug (PD-1 inhibitor). Ruptured liver cancer is a life-threatening emergency, and this study aims to understand how well this combined approach works after emergency bleeding has been controlled. **You may be eligible if...** - You have a confirmed diagnosis of primary liver cancer (HCC) - Your cancer ruptured but bleeding has been successfully controlled - You are receiving lenvatinib and a PD-1 inhibitor as your first systemic therapy - You are also receiving TACE (a procedure to block blood supply to the tumor) - Your liver function is adequate (Child-Pugh A or B) **You may NOT be eligible if...** - You have previously received other systemic liver cancer treatments - Your liver function is severely impaired - You have not had bleeding controlled before enrollment Talk to your doctor to see if this trial is right for you.